Evidence map›Paper›PMID 40718979›Full record

ArticleHuman vaccines & immunotherapeutics2025

Application of monoclonal antibodies in diabetes: A bibliometric analysis from 2004-2024.

Rui Wei, Bochao Jia, Shuang Zheng, Xuexue Zhang, Miaoran Wang, Ning Sun, Rui Zhang, Qiuyan Li

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rui WeiXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Bochao JiaSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Shuang ZhengXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Xuexue ZhangXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Miaoran WangXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Ning SunXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Rui ZhangXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Qiuyan LiXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.ORCID 0000-0002-8183-9945

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) have shown significant promise in diabetes treatment through immunobiological mechanisms. To comprehensively understand the current development status and future trends of this research field, this study used bibliometric methods to retrieve literature data from the Web of Science Core Collection database from 2004 to 2024 and conducted a comprehensive analysis using R software and VOSviewer. A total of 900 papers were published by 4,678 authors from 56 countries, with global publication volume and average citation frequency peaking in 2019, after which the field entered a stable development phase. The United States emerged as the leading contributor in terms of total publications, citations, and national collaborations. The journal

Indexed as

Antibodies, MonoclonalBibliometricsDiabetes MellitusDiabetes Mellitus, Type 1AnimalsClinical Trials as TopicHumansAntibodies, MonoclonalbibliometricdiabetesMonoclonal antibodiesresearch focusvisualization

Identifiers

PMID40718979
PMCPMC12309543

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.